Singapore markets closed
  • Straits Times Index

    3,111.65
    +18.85 (+0.61%)
     
  • Nikkei

    26,491.97
    +320.72 (+1.23%)
     
  • Hang Seng

    21,719.06
    +445.19 (+2.09%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • BTC-USD

    21,150.87
    -148.63 (-0.70%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • FTSE Bursa Malaysia

    1,436.70
    +5.65 (+0.39%)
     
  • Jakarta Composite Index

    7,042.94
    +44.67 (+0.64%)
     
  • PSE Index

    6,217.56
    +152.33 (+2.51%)
     

Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Mirati Therapeutics MRTX announced that it has filed a marketing authorization application (MAA) in the European Union (EU) for its KRAS-G12C inhibitor adagrasib for non-small cell lung cancer (NSCLC).

The MAA filed with the European Medicines Agency (EMA) seeks approval for adagrasib as a potential treatment for patients with KRAS-G12C-mutated NSCLC. The patients must have received at least one prior systemic therapy.

MRTX already submitted a new drug application (NDA) with the FDA seeking approval under the accelerated pathway for adagrasib for the above-mentioned indication. In February, Mirati announced that the FDA accepted the NDA and set a PDUFA action date of Dec 14, 2022, for the same.

Shares of Mirati have plunged 59.4% in the year-to-date period compared with the industry’s 24.1% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The filings in both the United States and the EU are based on positive top-line data from the phase II potentially registration-enabling monotherapy-cohort of the KRYSTAL-1 study, evaluating adagrasib for the above-mentioned indication. Data from the study was announced last Sepetmber. In the study, treatment with adagrasib led to an objective response rate of 43% and a disease control rate of 80% as of Jun 15, 2021.

Currently, there are very limited options available to patients suffering KRAS-G12C mutated NSCLC. A potential approval of adagrasib will provide Mirati with its first marketed drug and the patients with a new therapeutic option.

Mirati’s adagrasib, if approved, will face stiff competition from Lumakras, a KRAS-G12C inhibitor, marketed by Amgen AMGN. AMGN received accelerated approval for Lumakras as a second-line treatment for locally advanced or metastatic NSCLC from the FDA last May. Earlier in January this year, Amgen also gained approval for the drug in Europe for a similar indication. The drug has shown robust launch uptake since its approval, with Amgen recording revenues worth $62 million from its sales in first-quarter 2022.

The KRYSTAL-1 study is also evaluating adagrasib in multiple cohorts in combination with other therapies. These include a combo therapy of adagrasib with Merck’s MRK Keytruda for first-line NSCLC, a combination of adagrasib plus Boehringer Ingelheim’s Gilotrif (afatinib) for advanced NSCLC and adagrasib combined with Bristol-Myers’ BMY Erbitux for second-line colorectal cancer (CRC).

Preliminary data from the adagrasib plus Merck’s Keytruda cohort demonstrated that the combination achieved a 100% disease control rate, with all seven patients exhibiting tumor regression ranging from 37% to 92% as of Oct 21, 2021.

Mirati is also pursuing a broad combination development program for adagrasib beyond the combinations with Merck’s Keytruda and Bristol-Myers’ Erbitux. These include combinations with SHP2, SOS1 or CDK 4/6 inhibitors.

Both Opdivo and Keutruda are key drivers for Bristol Myers and Merck’s top lines, respectively. During the first quarter of 2022, Bristol Myers recorded $1.9 billion from Opdivo sales while Merck recorded $4.8 billion from Keytruda sales.

Mirati Therapeutics, Inc. Price

Mirati Therapeutics, Inc. Price
Mirati Therapeutics, Inc. Price

Mirati Therapeutics, Inc. price | Mirati Therapeutics, Inc. Quote

Zacks Rank

Mirati currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting